Western University

From the SelectedWorks of Edward Yu

Fall September 14, 2014

Use of protoporphyrin fluorescence to determine clinical target volume for non-melanotic skin cancers treated with primary radiotherapy

Stephanie Casey, *Western University*
Lara Best
Olga Vujovic, *Western University*
Kevin Jordan, *Western University*
Barbara Fisher, *Western University*, et al.

Western UNIVERSITY · CANADA

Available at: https://works.bepress.com/edwardyu/105/

Use of Protoporphyrin IX Fluorescence to Determine Clinical Target Volume for Non-Melanotic Skin Cancers Treated with Primary Radiotherapy

Casey S[1], Best L[1], Vujovic O[1], Jordan K[2], Fisher B[1], Carey D[2], Bourdeau D[2], Yu E[1]

Departments of Radiation Oncology[1], Physics[2], Radiotherapy[3]; London Regional Cancer Program, Western University

Schulich MEDICINE & DENTISTRY — Western UNIVERSITY · CANADA

London Health Sciences Centre — London Regional Cancer Program

Background

Squamous cell (SCC) and basal cell (BCC) of the skin continue to be the most commonly diagnosed cancers worldwide.[1] Radiotherapy provides local control of 90% and 80% for small and large BCCs respectively.[2,3]

The challenge with radiotherapy lies in determining treatment volumes, especially for poorly defined tumors. Photodynamic therapy (PDT), which involves preferential uptake of a photo-sensitizer that also fluoresces, provides a unique method that may increase accuracy for tumor delineation.[4,5]

Two previous surgical series (Brandt, Tierney) demonstrated that protoporphyrin IX (PpIX) fluorescence strongly correlates with the surgical extent of disease.[4,6]

This study prospectively investigated PpIX fluorescence as a means of determining the clinical target volume (CTV) necessary to encompass disease for non-melanotic skin cancers.

Materials and Methods

33 biopsy proven SCCs or BCCs. 7 were controls (well demarcated), 26 were poorly demarcated (experimental group).

Gross lesion size recorded (GTV)

↓

ALA, MAL applied, left on 2 hours

↓

Lesion fluorescence recorded (CTV)
Compared to: 5mm expansion if well demarcated, or 10mm if poorly demarcated

↓

Lesion treated to PTV (CTV + 2-3mm), 50Gy in 20 fractions



Figure 1: lesion under white light



Figure 2: lesion after PpIX fluorescence

Results

Table 1: Average PpIX CTV margin

	Control	Study
Patients	7	26
Standard CTV	5mm	10mm
← →	p=0.50	p=0.01
Max PpIX CTV	9mm	14mm
	Nose	**Other**
Patients	17	16
PpIX CTV	14mm	14mm
	p=0.11	p=0.04
Multi-focal	94%	44%

Figure 3: treatment plan



Follow-up

Average follow-up was 14 months. 1 local recurrence, was excised Nov. 2012. Patient died 11 months post-excision. 1 distant recurrence – axillary metastases 1 month after completion. Died 7 months after therapy.

Conclusions

PpIX photo-delineation suggests that 10 mm margins may inadequately cover areas of subclinical disease in poorly demarcated skin tumors. Long follow-up may be necessary to determine if this increase in CTV is clinically significant. PpIX photo-delineation also demonstrated that most nasal lesions are multifocal and thus, treatment of the entire nose should be considered.

References

1. American Joint Committee on Cancer. Chapter 29: Cutaneous squamous cell carcinoma and other cutaneous carcinomas. AJCC cancer staging handbook. 7th Ed. Pp359376.
2. Veness MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imag Rad Oncol 2008; 52: 278-86.
3. Veness MJ, Ang KK. Chapter 39: Cutaneous Malignancies. Clinical Radiation Oncology 3rd Edition. Gunderson & Tepper. Elsevier, 2012. Philadelphia. Pp756-67.
4. Brandt MG, Moore CC, Jordan K. Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies. J Otolaryngol 2007; 36(3): 148-155
5. Lee Y, Baron ED. Photodynamic therapy: current evidence and applications in dermatology. Sem Cutan Med Surg 2011; 30: 199-209
6. Tierney E, Petersen J, Hanke CW. Photodynamic diagnosis of tumor margins using methyl animolevulinate befores Mohs micrographic surgery. J Am Acad Dermatol 2011; 64: 911-8